Office for Technology Commercialization

Robert Vince – Antiviral Drug Design, Carbocyclic Nucleosides, Protease Inhibitor, Integrase Enzyme Inhibitors, Reverse Transcriptase, Abacavir

Technology #vince

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Robert Vince
Robert Vince, PhD
Director, Center for Drug Design
External Link (

Dr. Vince came to the University of Minnesota is 1967 after receiving his PhD in Medicinal Chemistry from the University of Buffalo. His research included the characterization of carbocyclic nucleoside analogues, which appeared to have promising anticancer and antiviral activity. This led to the development of abacavir, which Glaxo licensed and released as Ziagen. Dr. Vince established the Center for Drug Design (CDD) in 2002 and has been its director since that time. The CDD combines research and scholarship to develop novel drugs for therapeutic applications, such as HIV, cancer, neurological diseases, dermatological agents, infectious diseases, novel processes, and medical devices.

Dr. Vince has received many awards during his career. The National Cancer Institute honored him with a career development award (1972-1976) and most recently, in 2016, he received the Antonin Holy Memorial Lecture Award from the International Society for Antiviral Research. Dr. Vince was inducted into the Minnesota Science and Technology Hall of Fame (2011), the Minnesota Inventors Hall of Fame (2010) and the American Chemical Society Medicinal Chemistry Hall of Fame (2007). In 2014, the University of Minnesota presented him with the inaugural Impact Award, which recognizes an inventor for the significance and importance of his or her inventions. Robert Vince holds several patents for his discoveries.

Technologies available to license:
Early Alzheimer’s Detection Imaging System
Alzheimer’s and Neurodegenerative Disease Treatment

Learn more about Dr. Vince and his research:
Faculty Page
Center for Drug Design